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Introduction {#embj201798615-sec-0001}
============

Polycystic renal diseases belong to a spectrum of inherited disorders termed ciliopathies. They include genetically distinct and morphologically heterogeneous disorders that manifest at any time from early childhood to late in life and lead to end‐stage kidney disease in the majority of cases (Braun & Hildebrandt, [2016](#embj201798615-bib-0008){ref-type="ref"}). In adults, they present as autosomal dominant polycystic kidney disease (ADPKD), one of the most common monogenetic disorders in man, with large numbers of cysts leading to massive enlargement of the kidneys (Ong *et al*, [2015](#embj201798615-bib-0058){ref-type="ref"}). In children, the most prevalent form is nephronophthisis (NPHP). These kidneys are mostly small and fibrotic and contain only few cysts (Wolf, [2015](#embj201798615-bib-0094){ref-type="ref"}; Konig *et al*, [2017](#embj201798615-bib-0044){ref-type="ref"}). Important progress has been made in identifying the genetic causes of these entities: ADPKD is caused by mutations in either *PKD1* or *PKD2* (The International Polycystic Kidney Disease Consortium, [1995](#embj201798615-bib-1000){ref-type="ref"}; Mochizuki *et al*, [1996](#embj201798615-bib-0054){ref-type="ref"}). The number of *NPHP* genes has surpassed 20 and is growing annually (Hildebrandt *et al*, [1997](#embj201798615-bib-0033){ref-type="ref"}; Saunier *et al*, [1997](#embj201798615-bib-0073){ref-type="ref"}; Braun & Hildebrandt, [2016](#embj201798615-bib-0008){ref-type="ref"}). Yet, very few insights exist into what links these diverse genes to the disease manifestations of cysts, inflammation, and fibrosis.

A key to this question lies in cilia, cell organelles that contain proteins mutated in the ciliopathies. Apart from kidney disease, ciliopathies also affect the liver, the central nervous system, and the skeleton (Hildebrandt *et al*, [2011](#embj201798615-bib-0034){ref-type="ref"}). Motile cilia occur in bundles in the airways and brain, whereas primary cilia are non‐motile filiform structures at the surface of most cell types, including renal tubules (Drummond, [2012](#embj201798615-bib-0020){ref-type="ref"}). Cilia contain a microtubule‐based cytoskeleton, an ultrastructural gate, and a complex macromolecular transport system (Nachury, [2014](#embj201798615-bib-0055){ref-type="ref"}; Stepanek & Pigino, [2016](#embj201798615-bib-0082){ref-type="ref"}; Garcia‐Gonzalo & Reiter, [2017](#embj201798615-bib-0027){ref-type="ref"}). They act as signal transducers receiving physical and chemical stimuli (Praetorius & Spring, [2001](#embj201798615-bib-0065){ref-type="ref"}; Corbit *et al*, [2005](#embj201798615-bib-0016){ref-type="ref"}; Lechtreck *et al*, [2009](#embj201798615-bib-0046){ref-type="ref"}; Boehlke *et al*, [2010b](#embj201798615-bib-0005){ref-type="ref"}) and affect a wide range of autonomous cellular functions such as cell size, polarity, cell cycle, and migration (Kim *et al*, [2004](#embj201798615-bib-0043){ref-type="ref"}; Park *et al*, [2006](#embj201798615-bib-0060){ref-type="ref"}; Robert *et al*, [2007](#embj201798615-bib-0071){ref-type="ref"}; Jones *et al*, [2008](#embj201798615-bib-0041){ref-type="ref"}; Vasilyev *et al*, [2009](#embj201798615-bib-0089){ref-type="ref"}; Boehlke *et al*, [2010b](#embj201798615-bib-0005){ref-type="ref"}; Schneider *et al*, [2010](#embj201798615-bib-0075){ref-type="ref"}; Orhon *et al*, [2016](#embj201798615-bib-0059){ref-type="ref"}). However, it is unclear how the dysfunction of cilia explains the phenotype of renal ciliopathies.

When exploring this question, two observations prompted our attention. First, apart from cysts, ADPKD and NPHP share an inflammatory phenotype: In NPHP, inflammation and subsequent fibrosis are much more prominent than cysts (Hildebrandt *et al*, [1997](#embj201798615-bib-0033){ref-type="ref"}; Saunier *et al*, [1997](#embj201798615-bib-0073){ref-type="ref"}; Wolf, [2015](#embj201798615-bib-0094){ref-type="ref"}; Braun & Hildebrandt, [2016](#embj201798615-bib-0008){ref-type="ref"}; Slaats *et al*, [2016](#embj201798615-bib-0080){ref-type="ref"}). Likewise, in ADPKD macrophage infiltration occurs early on and promotes cyst enlargement (Karihaloo *et al*, [2011](#embj201798615-bib-0042){ref-type="ref"}). Similarly to NPHP, the late stages of ADPKD are characterized by a severe degree of fibrosis (Norman, [2011](#embj201798615-bib-0057){ref-type="ref"}; Ong *et al*, [2015](#embj201798615-bib-0058){ref-type="ref"}). The second aspect concerns the fact that metabolic signaling has been observed to contribute to ADPKD and NPHP (Chaki *et al*, [2012](#embj201798615-bib-0014){ref-type="ref"}; Rowe *et al*, [2013](#embj201798615-bib-0072){ref-type="ref"}; Menezes *et al*, [2016](#embj201798615-bib-0052){ref-type="ref"}). We therefore asked the question how cilia, metabolic signal transducers, and inflammation are linked.

An interesting candidate to explore this question is the kinase liver kinase B1 (LKB1). Liver kinase B1 is a metabolic sensor localized in cilia (Boehlke *et al*, [2010b](#embj201798615-bib-0005){ref-type="ref"}; Mick *et al*, [2015](#embj201798615-bib-0053){ref-type="ref"}). We have previously shown *in vitro* that bending of cilia under flow activates LKB1 to phosphorylate its target AMPK (5′‐adenosine monophosphate‐activated protein kinase) at the base of cilia and to regulate metabolic signaling linked to PKD (Boehlke *et al*, [2010b](#embj201798615-bib-0005){ref-type="ref"}; Walz *et al*, [2010](#embj201798615-bib-0090){ref-type="ref"}; Liu *et al*, [2014](#embj201798615-bib-0048){ref-type="ref"}; Orhon *et al*, [2016](#embj201798615-bib-0059){ref-type="ref"}). To explore the role of LKB1 *in vivo*, we inactivated LKB1 in the kidney. First, we asked whether renal deletion of LKB1 induces a renal ciliopathy phenotype. Second, we sought to uncover molecular mechanisms connecting LKB1, cilia, and PKD proteins to cysts, inflammation, and fibrosis.

Results {#embj201798615-sec-0002}
=======

Deletion of LKB1 in the kidney disrupts renal morphology and function {#embj201798615-sec-0003}
---------------------------------------------------------------------

Mono‐allelic mutations in the gene *STK11/LKB1* in humans cause Peutz‐Jeghers disease, an inherited cancer syndrome characterized by benign tumors of the skin and intestine, as well as the development of malignancies (Hemminki *et al*, [1998](#embj201798615-bib-0032){ref-type="ref"}). *Lkb1* ^−/−^ mice display severe developmental defects leading to embryonic lethality. We therefore pursued a kidney‐specific knockout strategy and crossed *Lkb1* ^flox/flox^ mice (Nakada *et al*, [2010](#embj201798615-bib-0056){ref-type="ref"}) with a kidney‐specific deleter strain to excise *Lkb1* in the distal nephron. LKB1 was absent from the cilia of these tubule segments (*Lkb1* ^ΔTub^; Figs [1](#embj201798615-fig-0001){ref-type="fig"}A and B, and [EV1](#embj201798615-fig-0001ev){ref-type="fig"}A--C), but the number and morphology of cilia were unchanged (Fig [EV1](#embj201798615-fig-0001ev){ref-type="fig"}D--F). The first sign of a renal disturbance was impaired urine concentration, which occurred at 5 weeks (Figs [1](#embj201798615-fig-0001){ref-type="fig"}C and [EV1](#embj201798615-fig-0001ev){ref-type="fig"}G--I); magnetic resonance imaging (MRI) studies confirmed that increased amounts of urine were present in the renal pelvis and occasionally demonstrated a few cysts (Fig [1](#embj201798615-fig-0001){ref-type="fig"}C). Macroscopically, the kidneys diminished in size over time (Fig [EV1](#embj201798615-fig-0001ev){ref-type="fig"}J and K; [Appendix Fig S1](#embj201798615-sup-0001){ref-type="supplementary-material"}). The occurrence of cysts was noted at the cortico‐medullary junction (Fig [1](#embj201798615-fig-0001){ref-type="fig"}C and F; 14 and 23 weeks). Histology revealed dilated tubules, thickened tubular basement membranes, interstitial inflammation, and fibrosis (Fig [1](#embj201798615-fig-0001){ref-type="fig"}G and H). These findings are similar to those of a previous study, which investigated renal metabolism using the same mouse genotype that was created independently (Han *et al*, [2016](#embj201798615-bib-0400){ref-type="ref"}).[1](#embj201798615-note-0001){ref-type="fn"} Collagen synthesis, a marker for extracellular matrix deposition, was increased (Fig [EV1](#embj201798615-fig-0001ev){ref-type="fig"}L), and renal failure ensued (Fig [1](#embj201798615-fig-0001){ref-type="fig"}D and E). Analogous to humans with Peutz‐Jeghers syndrome, heterozygote animals had normal renal function and histology ([Appendix Fig S1](#embj201798615-sup-0001){ref-type="supplementary-material"}). These findings show that LKB1 is required for normal morphology and function of the kidney. Loss of LKB1 in the kidney results in alterations of tubular architecture, cysts, and chronic inflammation with progressive scarring leading to renal failure, reminiscent of a renal ciliopathy phenotype.

![Loss of *Lkb1* in the mouse kidney disrupts renal architecture and causes inflammation and fibrosis\
LKB1 immunostaining in kidneys from control and *Lkb1* ^ΔTub^ mice at 5 weeks. Representative images of *n *=* *5 mice/group. Scale bars: 200 μm. See also Fig [EV1](#embj201798615-fig-0001ev){ref-type="fig"}A and B.Representative confocal microscopy images of collecting duct (CD, AQP2 expressing) from 5‐week‐old control (*n *=* *4) and *Lkb1* ^ΔTub^ (*n *=* *5) animals. LKB1 is not expressed in CD primary cilia (Ac‐Tub) of *Lkb1* ^ΔTub^ mice. Scale bars: 2 μm. See also Fig [EV1](#embj201798615-fig-0001ev){ref-type="fig"}C.Magnetic resonance tomography images obtained at 10 and 16 weeks. Representative images of coronal kidney sections of *n *=* *3 mice/group at 10 weeks and *n *=* *5 (control) and *n *=* *8 (*Lkb1* ^ΔTub^) at 16 weeks. Scale bars: 2 mm. See also [Appendix Fig S1A](#embj201798615-sup-0001){ref-type="supplementary-material"}.Plasma blood urea nitrogen (BUN) at 5, 14, and 23 weeks (w).Kaplan--Meier survival curves of control (*n *=* *13) and *Lkb1* ^ΔTub^ (*n *=* *15) mice.Periodic acid--Schiff (PAS) staining from control (5 weeks) and *Lkb1* ^ΔTub^ mice at 5, 14, and 23 weeks. Arrowheads indicate cysts. *Lkb1* ^ΔTub^ mice: representative of *n *=* *13 (5 weeks), *n *=* *12 (14 weeks), and *n *=* *10 (23 weeks). Scale bar: 1 mm.Higher magnification of PAS‐ and Picrosirius Red (lower right)‐stained sections showing dilated tubules (upper left), thickened tubular basement membranes (arrowheads, upper right), interstitial inflammation (lower left), and interstitial fibrosis (lower right) in 23‐week‐old *Lkb1* ^ΔTub^ mice. Scale bar: 50 μm. See also Fig [EV1](#embj201798615-fig-0001ev){ref-type="fig"}L.Transmission electron microscopy of distal tubule from 14‐week‐old *Lkb1* ^ΔTub^ mice. Dotted lines indicate thickening of basement membrane (lower panel). Representative images of *n *=* *3 mice. Scale bars: 2 μm.Data information: In (D, E), filled circles: control mice; and open circles: *Lkb1* ^ΔTub^ mice. Each circle represents one individual mouse. In (D), bars indicate mean. Mann--Whitney, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001.](EMBJ-37-e98615-g002){#embj201798615-fig-0001}

![Characterization of kidneys from *Lkb1* ^ΔTub^ mice\
A, BWestern blot (A) and quantification (B) of LKB1 expression in kidney medulla lysates from control and *Lkb1* ^ΔTub^ mice at 5 weeks. The remaining LKB1 protein derives from proximal tubule segments and glomeruli that are not targeted by *Ksp‐Cre*.CRepresentative confocal microscopy images of descending thin limb of Henle (AQP1 expressing) and thick ascending limb of Henle (Tamm‐Horsfall expressing, THP) from 5‐week‐old control (*n *=* *4) and *Lkb1* ^ΔTub^ (*n *=* *5) animals. LKB1 is present in cilia (Ac‐Tub) from AQP1‐expressing tubules (upper panel: control mice; lower panel *Lkb1* ^ΔTub^ mice) and THP‐positive tubules of control animals, but not in cilia from THP‐positive tubules of *Lkb1* ^ΔTub^ mice, where *Ksp‐Cre* is active. Scale bars: 2 μm.D, EStaining (D) and quantification (E) of primary cilia (Ac‐Tub) in collecting duct (CD) (Dolichos Biflorus Agglutinin expressing, DBA) at 5 weeks. Representative images of 5 mice/group. Blinded quantification of ten fields of view per biological sample. Scale bar: 50 μm.FScanning electron micrographs of CD at 5 weeks. Representative images of 5 mice/group. Scale bar: 20 μm, high magnification (right): 1 μm.GSpot urine from 5‐week‐old animals.H, IUrinary flow rate (H) and urine osmolality (I) at 5, 14, and 23 weeks.JRepresentative kidneys from control and *Lkb1* ^ΔTub^ mice at 23 weeks. Scales in cm.KKidney weight (KW)‐to‐body weight (BW) ratio at 5, 14, and 23 weeks.LRenal collagen mRNA content evaluated by qRT--PCR at 5 and 23 weeks.Data information: In (B, E, H, I, K, L), filled circles: control mice; and open circles: *Lkb1* ^ΔTub^ mice. Each circle represents one individual mouse. Bars indicate mean. Mann--Whitney, \**P *\<* *0.05, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001, *ns*: not statistically different. w: weeks.Source data are available online for this figure.](EMBJ-37-e98615-g003){#embj201798615-fig-0001ev}

LKB1 interacts with ciliopathy proteins, and a functional interaction exists between LKB1 and NPHP1 {#embj201798615-sec-0004}
---------------------------------------------------------------------------------------------------

To obtain insights into what might explain the phenotype of LKB1 deletion in the kidney, we performed a proteomic screen in protein lysates from renal medulla, aiming to identify endogenous interactors of LKB1 that might illuminate its function. The LKB1 precipitates obtained from these lysates were highly enriched for the known LKB1 interactor STRADa and 30 other proteins (Fig [2](#embj201798615-fig-0002){ref-type="fig"}A and [Datasets EV1](#embj201798615-sup-0003){ref-type="supplementary-material"} and [EV2](#embj201798615-sup-0004){ref-type="supplementary-material"}). Of these, 12 have previously been implicated in renal physiology or development ([Dataset EV1](#embj201798615-sup-0003){ref-type="supplementary-material"}). Two of them have been linked to the renal ciliopathy nephronophthisis (NPHP): ANKS3 (ankyrin repeat and sterile alpha motif domain containing 3) and NEK7 (NIMA (never in mitosis gene A)‐related kinase 7). ANKS3 is a ciliopathy protein and a known interactor of several proteins involved in NPHP, including NPHP1 (Leettola *et al*, [2014](#embj201798615-bib-0047){ref-type="ref"}; Yakulov *et al*, [2015](#embj201798615-bib-0095){ref-type="ref"}; Shamseldin *et al*, [2016](#embj201798615-bib-0077){ref-type="ref"}), the protein mutated in 60% of patients with genetically defined NPHP (Hildebrandt *et al*, [1997](#embj201798615-bib-0033){ref-type="ref"}; Saunier *et al*, [1997](#embj201798615-bib-0073){ref-type="ref"}; Halbritter *et al*, [2013](#embj201798615-bib-0031){ref-type="ref"}; Konig *et al*, [2017](#embj201798615-bib-0044){ref-type="ref"}). ANKS3 also has a physical and functional interaction with NEK7, and NEK7 is part of the cilia proteome (Mick *et al*, [2015](#embj201798615-bib-0053){ref-type="ref"}; Ramachandran *et al*, [2015](#embj201798615-bib-0068){ref-type="ref"}). We confirmed the endogenous interaction between LKB1, ANKS3, and NEK7 by co‐immunoprecipitations from renal medulla (Fig [2](#embj201798615-fig-0002){ref-type="fig"}B) and found that ANKS3 localizes to cilia (Fig [2](#embj201798615-fig-0002){ref-type="fig"}C--E and [Appendix Fig S3F](#embj201798615-sup-0001){ref-type="supplementary-material"}).

![LKB1 interacts with ANKS3, NEK7, and NPHP1\
LKB1 interactors identified by a proteomic screen in mouse kidney medulla. See also [Datasets EV1](#embj201798615-sup-0003){ref-type="supplementary-material"} and [EV2](#embj201798615-sup-0004){ref-type="supplementary-material"}.Immunoprecipitates (IP) from mouse kidney medulla. ANKS3 and NEK7 are enriched in the LKB1 precipitates. Representative Western blot of three independent experiments. Expected molecular weights: ANKS3 (72 kDa), LKB1 (54 kDa), and NEK7 (35 kDa).Representative confocal microscopy images of primary cilia (acetylated tubulin expressing, Ac‐Tub) and ANKS3 in MDCK cells expressing inducible shRNA against Anks3 (Anks3‐i1) after tetracycline induction (Tet). Scale bar: 5 μm. See also [Appendix Fig S3F](#embj201798615-sup-0001){ref-type="supplementary-material"}.Quantification of ANKS3‐positive primary cilia in Anks3‐i1 MDCK cells. Blinded quantification of five fields of view per biological replicate.Confocal microscopy images of collecting duct (AQP2 expressing) from 5‐week‐old wild‐type mice. Anti‐ANKS3 antibody (upper panel), but not control IgG (lower panel), detects a signal in cilia (Ac‐Tub). Representative images of *n *=* *5 mice. Scale bar: 5 μm.IP from HEK 293T cells. Endogenous LKB1 is enriched in the precipitates of FLAG‐NPHP1. Representative Western blot of three independent experiments. See also Fig [EV2](#embj201798615-fig-0002ev){ref-type="fig"}A--C.Zebrafish embryos injected with control morpholino (MO) or MO targeting *nphp1* at 48 h post‐fertilization. Arrowheads indicate pronephric cysts. Scale bar: 100 μm.Quantification of embryos with pronephric cysts. Numbers in bars represent *n* analyzed embryos.Data information: In (D), each circle represents one biological replicate. Bars indicate mean. Paired *t*‐test, \**P *\<* *0.05. In (H) mean ± SD. ANOVA followed by the Tukey--Kramer test, \**P *\<* *0.05, \*\**P *\<* *0.01.Source data are available online for this figure.](EMBJ-37-e98615-g004){#embj201798615-fig-0002}

The interaction between LKB1 and two cilia proteins associated with NPHP1 is interesting, since the phenotype of the *Lkb1* ^ΔTub^ mice resembles NPHP in children. Furthermore, it suggests a functional synergy between LKB1 and NPHP1. Indeed, LKB1 co‐immunoprecipitated with NPHP1 (Figs [2](#embj201798615-fig-0002){ref-type="fig"}F and [EV2](#embj201798615-fig-0002ev){ref-type="fig"}A), but interacted only weakly with NPHP2, NPHP3, NPHP4, and NPHP8 (Fig [EV2](#embj201798615-fig-0002ev){ref-type="fig"}B and C). To test whether LKB1 and NPHP1 have a functional interaction, we used zebrafish, an established model for ciliopathy phenotypes (Kramer‐Zucker *et al*, [2005](#embj201798615-bib-0045){ref-type="ref"}; Tuz *et al*, [2014](#embj201798615-bib-0086){ref-type="ref"}). Morpholino‐mediated knockdown of NPHP proteins and *anks3* in zebrafish larvae results in the formation of pronephric cysts (Yakulov *et al*, [2015](#embj201798615-bib-0095){ref-type="ref"}). We found that knockdown of *nphp1* caused cyst formation in a minority of larvae, whereas knockdown of *lkb1* alone had no effect (Fig [2](#embj201798615-fig-0002){ref-type="fig"}G and H). However, co‐injection of both morpholinos strongly increased the proportion of larvae with a cystic phenotype (Fig [2](#embj201798615-fig-0002){ref-type="fig"}H). Taken together, these findings link LKB1 and NPHP1 in physical and functional terms. They suggest that LKB1 is in a complex with NPHP1, ANKS3, and NEK7, and open the possibility that this module regulates signaling events downstream of cilia relevant to the observed renal phenotype.

![Immunoprecipitation experiments (IP) from HEK 293T cells\
AFLAG.LKB1 is enriched in the precipitates of V5.NPHP1 and V5.STRADa, but not V5.GFP.B, CEndogenous LKB1 is enriched in the precipitates of FLAG (B)‐ or V5‐tagged (C) NPHP1 but interacts weakly with NPHP2, NPHP3, NPHP4, and NPHP8.DEndogenous NPHP1 is enriched in the precipitates of FLAG.LKB1 and FLAG.STRADs but not FLAG.MO25s or FLAG.GFP.Data information: Representative Western blot of at least three independent experiments.Source data are available online for this figure.](EMBJ-37-e98615-g005){#embj201798615-fig-0002ev}

Loss of LKB1 results in epithelial upregulation of CCL2 and is associated with the accumulation of CCR2^+^ macrophages {#embj201798615-sec-0005}
----------------------------------------------------------------------------------------------------------------------

We were interested in the downstream events explaining the inflammation and fibrosis in *Lkb1* ^ΔTub^ kidneys. The best characterized target of LKB1 signaling is the AMP sensing kinase AMPK, but other downstream substrates are known (Lizcano *et al*, [2004](#embj201798615-bib-0049){ref-type="ref"}; Shaw *et al*, [2004](#embj201798615-bib-0079){ref-type="ref"}). LKB1 phosphorylates AMPK to inhibit mTORC1 and protein synthesis. We did not find consistent signals demonstrating dysregulation of AMPK or mTORC1 signaling in the tubules of *Lkb1* ^ΔTub^ kidneys ([Appendix Fig S2](#embj201798615-sup-0001){ref-type="supplementary-material"}), suggesting that alternative signaling events triggered by LKB1 inactivation are involved in the renal pathology. To approach this issue in an unbiased fashion, we performed microarray analysis in *Lkb1* mutant kidneys at an early time point, when there was only little damage to the parenchyma (Fig [1](#embj201798615-fig-0001){ref-type="fig"}F; 5 weeks). We compared these data with RNAseq analyses performed in MDCK cells where *Lkb1* was depleted by shRNA‐induced knockdown (Boehlke *et al*, [2010b](#embj201798615-bib-0005){ref-type="ref"}; Figs [3](#embj201798615-fig-0003){ref-type="fig"}A and [EV3](#embj201798615-fig-0003ev){ref-type="fig"}A and B, and [Dataset EV3](#embj201798615-sup-0005){ref-type="supplementary-material"}). This approach allowed us to discard regulated transcripts from the kidney that came from outside renal epithelia. At the same time, it enabled us to look at transcripts that we might have discarded, if we had assumed that they originate in non‐epithelial cells, for instance immune cells. Network analysis of clustered GO terms for the 99 commonly upregulated genes revealed changes in biological processes relating to organ development, morphogenesis, and angiogenesis which are in keeping with the role of LKB1 in early development and cancer (Fig [EV3](#embj201798615-fig-0003ev){ref-type="fig"}C and [Dataset EV4](#embj201798615-sup-0006){ref-type="supplementary-material"}), while the 41 downregulated genes represented mostly metabolic processes ([Dataset EV5](#embj201798615-sup-0007){ref-type="supplementary-material"}). Surprisingly, the upregulated genes revealed clusters incorporating immune response, cytokine production, and immune cell migration (Fig [EV3](#embj201798615-fig-0003ev){ref-type="fig"}C). The two most highly upregulated genes in the renal tubular cell‐derived set that were co‐regulated *in vivo* were the cytokine‐inducible transcription factor ANKRD1 (ankyrin repeat domain 1) and the inducible cytokine CCL2 (chemokine (C‐C motif) ligand 2; Fig [3](#embj201798615-fig-0003){ref-type="fig"}B and [Dataset EV3](#embj201798615-sup-0005){ref-type="supplementary-material"}).

![Transcriptome analysis in LKB1‐deficient kidneys and a renal epithelial cell line depleted of LKB1\
Venn diagram of differentially regulated genes from *Lkb1*‐depleted MDCK cells (left Lkb1‐i1 + tetracycline) and kidneys from *Lkb1* ^*ΔTub*^ mice (right). Red numbers: upregulated; blue numbers: downregulated. See also Fig [EV3](#embj201798615-fig-0003ev){ref-type="fig"}A--C and Datasets [EV3](#embj201798615-sup-0005){ref-type="supplementary-material"}, [EV4](#embj201798615-sup-0006){ref-type="supplementary-material"} and [EV5](#embj201798615-sup-0007){ref-type="supplementary-material"}.Jointly up‐ and downregulated genes in the mouse (kidney dataset) and MDCK cells (cells dataset) (FDR \< 0.05, Pearson correlation *r* = 0.69). Genes with a combined fold change \> 0.6 are annotated. *Ccl2* and *Ankrd1* are referred to in the text. Solid line: linear fit; dotted lines: 95% confidence interval.*Ccl2* mRNA expression in kidney medulla from littermate control and *Lkb1* ^ΔTub^ mice at 5 weeks.*Ccl2* mRNA expression in MDCK cells expressing inducible shRNA against the indicated targets after tetracycline treatment (Tet). Luci‐i (shRNA against luciferase; *n *=* *7), Lkb1‐i1 (*n *=* *8), and Lkb1‐i1 rescue (*n *=* *5). See also Fig [EV3](#embj201798615-fig-0003ev){ref-type="fig"}D and [Appendix Fig S3A--C](#embj201798615-sup-0001){ref-type="supplementary-material"}.CCL2 secretion in Lkb1‐i1 MDCK cell supernatants after tetracycline induction (Tet). (*n *=* *5).Data information: In (C), each circle represents one individual mouse. Bars indicate mean. Mann--Whitney, \*\**P *\<* *0.01. In (D, E) mean ± SD. Paired *t*‐test, *\**\**P *\<* *0.01, *ns*: not statistically different.Source data are available online for this figure.](EMBJ-37-e98615-g006){#embj201798615-fig-0003}

![Transcriptional screens identify LKB1 as a regulator of CCL2\
APrincipal component analysis (PCA) of RNAseq expression levels from MDCK cells with inducible knockdown of Lkb1 (Lkb1‐i) after tetracycline incubation (PC1: −Tet vs. +Tet). *n *=* *2 biological replicates (PC2).BPCA of microarray expression data from littermate control and *Lkb1* ^ΔTub^ kidneys at 5 weeks (PC1). *n *=* *5 mice each (PC2). Replicates are enclosed in convex hulls to guide the eye.CNetwork representation of significantly enriched Biological Processes GO terms (commonly upregulated genes) derived from a hypergeometric test (*P *\< 0.05). Nodes are connected if they have a semantic similarity \> 0.6, and clusters are named according to the most representative GO terms. See also [Dataset EV4](#embj201798615-sup-0006){ref-type="supplementary-material"}.D--H*Ccl2* mRNA expression evaluated by qRT--PCR in MDCK cells expressing inducible shRNA after tetracycline induction (Tet) against Lkb1‐i2 (D, *n *=* *4), Lkb1‐i1 (E, *n *=* *3) after 5 h of 1 mM AICAR treatment, Anks3‐i2 (F, *n *=* *5), Nek7‐i2 (G, *n *=* *5), PKD1 KO1 Lkb1‐i1, and PKD1 KO2 Lkb1‐i1 (H, *n *=* *3). See also [Appendix Fig S3B, F, G and S](#embj201798615-sup-0001){ref-type="supplementary-material"}.Data information: In (D--H), mean ± SD. Paired *t*‐test, \**P *\<* *0.05, *\**\**P *\<* *0.01, *ns*: not statistically different.](EMBJ-37-e98615-g007){#embj201798615-fig-0003ev}

CCL2 (also known as monocyte chemoattractant protein 1 or MCP1) is a potent chemoattractant of bone marrow‐derived CCR2^+^ blood monocytes which are critical progenitors for tissue macrophages in many pathological conditions, including bacterial immunity, tumors, and inflammation (Serbina & Pamer, [2006](#embj201798615-bib-0076){ref-type="ref"}; Franklin *et al*, [2014](#embj201798615-bib-0026){ref-type="ref"}; Cao *et al*, [2015](#embj201798615-bib-0012){ref-type="ref"}). As CCL2 has been shown to promote macrophage recruitment and disease progression in chronic kidney disease (Cao *et al*, [2015](#embj201798615-bib-0012){ref-type="ref"}), we focused our attention on this protein. CCL2 upregulation was confirmed in *Lkb1* mutant kidneys as well as in cells after shRNA‐mediated depletion of LKB1 and was prevented by AICAR treatment (Figs [3](#embj201798615-fig-0003){ref-type="fig"}C--E and [EV3](#embj201798615-fig-0003ev){ref-type="fig"}D and E, and [Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}). These data identify CCL2 as a highly upregulated chemokine in the kidney after loss of LKB1 *in vivo*. Our *in vitro* data demonstrate that renal tubular cells are the source of CCL2 in LKB1 deficiency.

To better characterize the local inflammatory response triggered by inactivation of *Lkb1 in vivo*, we analyzed renal cell suspensions from *Lkb1* mutant mice and littermate controls by flow cytometry (Triantafyllopoulou *et al*, [2010](#embj201798615-bib-0085){ref-type="ref"}; [Appendix Fig S5](#embj201798615-sup-0001){ref-type="supplementary-material"}): *Lkb1* mutant mice contained significantly increased numbers of CD45‐positive leukocytes. This was in part explained by increased numbers of neutrophils, while B‐ and T‐cell numbers were not significantly changed. Strikingly, kidney monocytes and CD11b^hi^ macrophages expressing CCR2, the CCL2 receptor, were significantly increased (Fig [4](#embj201798615-fig-0004){ref-type="fig"}A--F and [Appendix Fig S5](#embj201798615-sup-0001){ref-type="supplementary-material"}). These findings support the notion that LKB1‐deficient renal epithelial cells in the kidney take on an inflammatory phenotype and release CCL2, resulting in the recruitment of mononuclear phagocytes and macrophage activation.

![Monocytes and CCR2^+^ macrophage accumulation in the kidneys of *Lkb1* ^ΔTub^ mice\
A, BFlow cytometry analysis (A) and absolute numbers (B) of kidney monocytes (F4/80^lo^CD11b^hi^, blue rectangles) at 10 weeks. See also [Appendix Fig S5](#embj201798615-sup-0001){ref-type="supplementary-material"}.C--EFlow cytometry analysis (C), percentage (D), and absolute numbers (E) of CCR2^+^ macrophages (F4/80^hi^CD11b^+^CCR2^+^, black rectangles) at 10 weeks.FFlow cytometry analysis of CD11b expression in F4/80^hi^CD11b^+^CCR2^+^ macrophages at 10 weeks.Data information: In (A, C), numbers below or above rectangles represent percentage of cells per area. In (B--E), each circle represents one individual mouse. Bars indicate mean. Mann--Whitney, \**P* \< 0.05, \*\**P* \< 0.01.](EMBJ-37-e98615-g008){#embj201798615-fig-0004}

The LKB1/NPHP1/ANKS3/NEK7 complex controls CCL2 expression {#embj201798615-sec-0006}
----------------------------------------------------------

The data described above raise two questions: (i) Does the complex of LKB1 with NPHP1, ANKS3, and NEK7 regulate CCL2? (ii) If so, does this regulation require cilia? To address the first question, we resorted to a loss‐of‐function approach using shRNA‐mediated knockdown in cultured renal epithelial cells. Remarkably, depletion of NPHP1 but not NPHP4 resulted in upregulation of *Ccl2* in MDCK cells (Fig [5](#embj201798615-fig-0005){ref-type="fig"}A and [Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}). Similar to the findings in NPHP1 or LKB1 knockdown cells, *Ccl2* was increased in cells depleted of ANKS3 or NEK7, while total LKB1 expression was not affected (Figs [5](#embj201798615-fig-0005){ref-type="fig"}B and [EV3](#embj201798615-fig-0003ev){ref-type="fig"}F and G, and [Appendix Figs S3 and S4](#embj201798615-sup-0001){ref-type="supplementary-material"}). This indicates that LKB1, NPHP1, ANKS3, and NEK7 act as signaling modules to suppress this chemokine.

![LKB1 acts in concert with NPHP1, ANKS3, and NEK7 to regulate CCL2 in a cilium‐dependent manner\
A, B*Ccl2* mRNA expression in MDCK cells expressing inducible shRNA against the indicated targets (+ Tet). Nphp1‐i (*n *=* *8), Nphp4‐i (*n *=* *4), Anks3‐i1 (*n *=* *5), and Nek7‐i1 (*n *=* *5). See also [Appendix Fig S3D--G](#embj201798615-sup-0001){ref-type="supplementary-material"}.CConfocal microscopy images of primary cilia (Ac‐Tub) and GFP in MDCK wild‐type cells (WT) or in MDCK cells expressing GFP alone or YFP constructs fused to LKB1 or STRAD proteins. GFP antibody was used to detect both GFP and YFP constructs. Representative images of three biological replicates. Scale bar: 1 μm.DRepresentative confocal microscopy images of primary cilia (Ac‐Tub) and LKB1 in MDCK cells expressing inducible shRNA against Stradb (Stradb‐i; + Tet). Scale bar: 5 μm (left panel) and 1 μm (right panel). See also [Appendix Fig S3I](#embj201798615-sup-0001){ref-type="supplementary-material"}.EQuantification of LKB1‐positive primary cilia in Stradb‐i MDCK cells. Blinded quantification of five fields of view per biological replicate.F*Ccl2* mRNA expression in Strada‐i (*n *=* *5) and Stradb‐i (*n *=* *5) MDCK cells. See also [Appendix Fig S3H and I](#embj201798615-sup-0001){ref-type="supplementary-material"}.G, H*Ccl2* mRNA expression in MDCK cells expressing inducible shRNA against the indicated targets (+ Tet). Kif3a‐i (*n *=* *7), Ift88‐i (*n *=* *4), Kif3a‐i;Lkb1‐i1 (*n *=* *3), and Ift88‐i;Lkb1‐i1 (*n *=* *4). See also [Appendix Fig S3J--M](#embj201798615-sup-0001){ref-type="supplementary-material"}.Data information: In (A, B, F--H), mean ± SD. Paired *t*‐test, \**P *\<* *0.05, *\**\**P *\<* *0.01, \*\*\**P *\<* *0.001, *ns*: not statistically different. In (E), each circle represents one biological replicate. Bars indicate mean. Paired *t*‐test, \**P* \< 0.05.](EMBJ-37-e98615-g010){#embj201798615-fig-0005}

The ciliary isoform of the LKB1 interactor STRAD is required for CCL2 regulation {#embj201798615-sec-0007}
--------------------------------------------------------------------------------

Liver kinase B1, in addition to the cilium, resides in the nucleus and the cytosol. To clarify whether the LKB1 module acts in cilia, we sought evidence that ciliary localization of LKB1 is required for suppression of CCL2. To address this question, we focused on the functional LKB1 interactors STRADa and STRADb (Zeqiraj *et al*, [2009](#embj201798615-bib-0097){ref-type="ref"}) which are part of a heterotrimeric complex and required for the kinase activity of LKB1 (Baas *et al*, [2003](#embj201798615-bib-0002){ref-type="ref"}; Boudeau *et al*, [2003](#embj201798615-bib-0007){ref-type="ref"}). Indeed, we found that NPHP1 interacts with STRAD, supporting a functional role of the LKB1--NPHP1 interaction (Fig [EV2](#embj201798615-fig-0002ev){ref-type="fig"}D). STRADb has been reported to mediate entry of LKB1 into cilia, whereas STRADa is required for LKB1 function in the cytosol (Boudeau *et al*, [2003](#embj201798615-bib-0007){ref-type="ref"}; Mick *et al*, [2015](#embj201798615-bib-0053){ref-type="ref"}). Indeed, we found that tagged versions of STRADb, but not STRADa, localized to cilia in MDCK cells (Fig [5](#embj201798615-fig-0005){ref-type="fig"}C). Furthermore, inducible knockdown of STRADb decreased the amount of LKB1 in the cilium (Fig [5](#embj201798615-fig-0005){ref-type="fig"}D and E and [Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}). Notably, depletion of STRADb recapitulated the *Ccl2* increase seen after LKB1 or NPHP1 depletion, whereas this was not the case for knockdown of STRADa (Fig [5](#embj201798615-fig-0005){ref-type="fig"}F and [Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}). Since STRADb is the functional interactor of LKB1 within the cilium, these data confirm that LKB1 is required within cilia to regulate CCL2.

Primary cilia are positive regulators of CCL2 {#embj201798615-sec-0008}
---------------------------------------------

At this point, our findings suggested two possible alternatives of how cilia might regulate CCL2. They could act either as negative regulators of CCL2, in which case removal of cilia would increase expression of CCL2, or as sensors of a CCL2‐inducing signal that is negatively regulated by the LKB1 module, in which case removal of the cilium would decrease CCL2 levels. A similar mechanism has been described for hedgehog, a developmental pathway that processes crucial signaling steps within cilia (Corbit *et al*, [2005](#embj201798615-bib-0016){ref-type="ref"}; Bangs & Anderson, [2017](#embj201798615-bib-0003){ref-type="ref"}). Indeed, we found the second possibility to be the case. We ablated cilia by interfering with intraflagellar transport (IFT). Targeting the ciliary kinesin subunit KIF3a or the IFT protein IFT88 prevents cells from forming cilia (Marszalek *et al*, [1999](#embj201798615-bib-0051){ref-type="ref"}; Pazour *et al*, [2000](#embj201798615-bib-0061){ref-type="ref"}; Boehlke *et al*, [2010b](#embj201798615-bib-0005){ref-type="ref"}). We found that cilia‐deficient compared to ciliated cells expressed lower levels of *Ccl2* (Fig [5](#embj201798615-fig-0005){ref-type="fig"}G and [Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}). Furthermore, co‐ablation of cilia together with LKB1 prevented the increase in *Ccl2* that is seen after LKB1 depletion alone (Fig [5](#embj201798615-fig-0005){ref-type="fig"}H and [Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}), suggesting that cilia are required for the upregulation of CCL2 and that the LKB1 module inhibits cilia‐induced CCL2 expression (Fig 8A and B).

PKD1 interacts with LKB1 and STRAD {#embj201798615-sec-0009}
----------------------------------

A cilia‐dependent cyst‐activating mechanism has been postulated for the ciliopathy ADPKD (Ma *et al*, [2013](#embj201798615-bib-0050){ref-type="ref"}). This mechanism is inhibited by PKD1 under physiological conditions and is released in the presence of a PKD mutation, driving cyst growth. However, the putative ciliary downstream signal has not been identified. We therefore wondered whether deregulated CCL2 control by dysfunction of the LKB1 module in cilia plays a role in ADPKD. Consistent with this notion, we found that PKD1 co‐immunoprecipitates with LKB1 and both STRADa and STRADb (Fig [6](#embj201798615-fig-0006){ref-type="fig"}A). Furthermore, analyzing PKD1‐null renal epithelial cells that were constructed using TALEN‐based genome editing ([Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}; Hofherr *et al*, [2017](#embj201798615-bib-0036){ref-type="ref"}), we observed that *Ccl2* was upregulated compared to wild‐type cells (Fig [6](#embj201798615-fig-0006){ref-type="fig"}B and C), analogous to our findings in LKB1‐depleted cells. Neither LKB1 nor other members of the regulatory complex were consistently altered in their expression ([Appendix Fig S4](#embj201798615-sup-0001){ref-type="supplementary-material"}). When we ablated cilia through depletion of KIF3a or IFT88 in *Pkd1*‐null cells, we found a marked decrease in *Ccl2* (Fig [6](#embj201798615-fig-0006){ref-type="fig"}D and [Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}). Simultaneous LKB1 depletion in PKD1 knockout cells, however, did not change *Ccl2* expression compared to PKD1 deletion alone (Fig [EV3](#embj201798615-fig-0003ev){ref-type="fig"}H and [Appendix Fig S3](#embj201798615-sup-0001){ref-type="supplementary-material"}), indicating that PKD1 is required for LKB1 to repress Ccl2 expression. Taken together, these findings, obtained *in vitro* in a cell‐based system, demonstrate that a physical and functional interaction exists between PKD1 and the LKB1 module. Our findings suggest that PKD1 and the LKB1 module form a functional unit to inhibit a ciliary CCL2‐inducing signal and that PKD1 is required for its function. This raised the possibility that deregulation of CCL2 may play a role in the pathological changes occurring in ADPKD.

![PKD1 interacts with LKB1 to prevent the cilium‐dependent CCL2 increase and inflammation\
AImmunoprecipitation (IP) from HEK 293T cells. FLAG‐PC1 is enriched in the precipitates of V5‐LKB1, V5‐STRADa, and V5‐STRADb. Representative Western blot of five independent experiments.B*Ccl2* mRNA expression in wild‐type (WT) and two PKD1‐null (KO1, KO2) MDCK cell lines constructed using TALEN‐based genome editing (*n* = 4). See also [Appendix Fig S3N--P](#embj201798615-sup-0001){ref-type="supplementary-material"}.CCCL2 secretion in WT and PKD1 KO1 and KO2 MDCK cell lines (*n *=* *3).D*Ccl2* mRNA expression in PKD1 KO1 MDCK cells expressing inducible shRNA against the indicated targets after tetracycline induction (Tet). WT (*n* = 4), Kif3a‐i (*n *=* *4), and Ift88‐i (*n *=* *4). See also [Appendix Fig S3Q and R](#embj201798615-sup-0001){ref-type="supplementary-material"}.ERepresentative kidneys from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ mice at 12 weeks. See also Fig [EV4](#embj201798615-fig-0004ev){ref-type="fig"}.FKidney weight (KW)‐to‐body weight (BW) ratio in control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ mice at 12 weeks.G*Ccl2* mRNA expression in kidneys from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ mice at 12 weeks.H, IFlow cytometry analysis (H) and absolute numbers (I) of CCR2^+^ macrophages (F4/80^hi^CD11b^+^CCR2^+^, black oval) in control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ mice at 12 weeks. See also [Appendix Fig S6](#embj201798615-sup-0001){ref-type="supplementary-material"}.J, KFlow cytometry analysis (J) and absolute numbers (K) of CCR2^+^ monocytes (F4/80^lo^CD11b^hi^CCR2^+^, black square) in control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ mice at 12 weeks.Data information: In (B--D), mean ± SD. Paired *t*‐test, \**P* \< 0.05. In (F, G, I, K), each dot represents one individual mouse. Bars indicate mean. ANOVA followed by the Tukey--Kramer test, \**P *\<* *0.05, \*\*\**P *\<* *0.001. In (H, J), numbers represent percentage of cells per gated region.Source data are available online for this figure.](EMBJ-37-e98615-g012){#embj201798615-fig-0006}

Cilia‐induced CCL2 promotes disease progression in a mouse model of ADPKD {#embj201798615-sec-0010}
-------------------------------------------------------------------------

Inflammation and fibrosis lead to a loss of parenchyma and small kidneys in patients with NPHP (Konig *et al*, [2017](#embj201798615-bib-0044){ref-type="ref"}). In ADPKD, however, macrophages have been shown to be activators of cyst growth, thus leading to kidney enlargement and disease progression (Karihaloo *et al*, [2011](#embj201798615-bib-0042){ref-type="ref"}), providing a rationale for the hypothesis that the regulatory effect of PKD1 and LKB1 on cilia‐induced CCL2 expression is relevant for human pathology. We tested this hypothesis in an orthologous model of ADPKD, where post‐natal inactivation of *Pkd1* results in slow‐onset PKD, recapitulating human disease (Ma *et al*, [2013](#embj201798615-bib-0050){ref-type="ref"}; Figs [6](#embj201798615-fig-0006){ref-type="fig"}E and F, and [EV4](#embj201798615-fig-0004ev){ref-type="fig"}). In these kidneys, we observed that an early stage of cyst formation was accompanied by the upregulation of *Ccl2* transcript but no change in LKB1 or other members of the regulatory complex (Fig [6](#embj201798615-fig-0006){ref-type="fig"}G and [Appendix Fig S4](#embj201798615-sup-0001){ref-type="supplementary-material"}). Flow cytometry analysis revealed that CCR2^+^ kidney mononuclear phagocytes were markedly increased in *Pkd1*‐deficient kidneys (Fig [6](#embj201798615-fig-0006){ref-type="fig"}H--K). In contrast, kidney B and T lymphocytes and neutrophils were not significantly increased at this early time point ([Appendix Fig S6](#embj201798615-sup-0001){ref-type="supplementary-material"}).

![*Kif3a* ablation ameliorates cyst formation in *Pkd1* mutant mice\
Age from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ mice.Plasma blood urea nitrogen (BUN) from control (*n *=* *16), i*Pkd1* ^ΔTub^ (*n *=* *10), and i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ (*n *=* *12) mice at 12 weeks.Representative periodic acid--Schiff (PAS)‐stained kidney sections from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ mice at 12 weeks.Higher magnification of PAS‐stained sections. Scale bar: 250 μm.Data information: In (A, B), each dot represents one individual mouse. Bars indicate mean. ANOVA followed by the Tukey--Kramer test, *ns*: not statistically different.](EMBJ-37-e98615-g009){#embj201798615-fig-0004ev}

To test whether cilia are required for the upregulation of CCL2 in *Pkd1*‐deficient kidneys, we generated mice with simultaneous targeting of *Pkd1* and *Kif3a*. As has been described (Ma *et al*, [2013](#embj201798615-bib-0050){ref-type="ref"}), these animals had a strongly ameliorated phenotype (Figs [6](#embj201798615-fig-0006){ref-type="fig"}E and F, and EV4). In line with our *in vitro* findings, disruption of ciliogenesis prevented *Ccl2* upregulation in *Pkd1*‐deficient kidneys (Fig [6](#embj201798615-fig-0006){ref-type="fig"}G). Concurrently, cilia ablation also decreased the numbers of CCR2^+^ mononuclear phagocytes (Fig [6](#embj201798615-fig-0006){ref-type="fig"}H--K).

This finding supports the hypothesis that cilia induce CCL2 in Pkd1‐deficient kidneys to recruit macrophages and drive cyst growth. However, it leaves the possibility that an unknown ciliary signal other than CCL2 drives cyst growth, affecting inflammation and immune cell‐mediated CCL2 expression by indirect means. To investigate this possibility, we inactivated *Pkd1* and *Ccl2* simultaneously in renal epithelial cells using the same Cre driver. As expected, this resulted in fewer macrophages and a strongly ameliorated phenotype (Figs [7](#embj201798615-fig-0007){ref-type="fig"}A--E and [EV5](#embj201798615-fig-0005ev){ref-type="fig"}). This finding confirms that tubular CCL2 drives ADPKD severity *in vivo*.

![Tubule‐derived CCL2 promotes macrophage recruitment and cyst formation in *Pkd1*‐targeted kidneys\
Representative kidneys from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^ mice at 13.5 weeks. See also Fig [EV5](#embj201798615-fig-0005ev){ref-type="fig"}.Kidney weight (KW)‐to‐body weight (BW) ratio in control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^ mice at 13.5 weeks.*Ccl2* mRNA expression in kidneys from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^ mice at 13.5 weeks.F4/80 immunostaining in kidneys from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^ mice at 13.5 weeks. Representative images of *n *=* *4 mice/group. Scale bars: 50 μm.*Itgam* mRNA expression in kidneys from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^ mice at 13.5 weeks.Data information: In (B, C, E), each dot represents one individual mouse. Bars indicate mean. ANOVA followed by the Tukey--Kramer test, \**P *\<* *0.05, \*\**P *\<* *0.01.](EMBJ-37-e98615-g013){#embj201798615-fig-0007}

![*Ccl2* ablation reduces cyst formation in *Pkd1* mutant mice\
Age from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^ mice.Plasma blood urea nitrogen (BUN) from control, i*Pkd1* ^ΔTub^, and i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^ mice at 13.5 weeks.Representative periodic acid--Schiff (PAS)‐stained kidney sections from control (*n *=* *7), i*Pkd1* ^ΔTub^ (*n *=* *6), and i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^ (*n *=* *7) mice at 13.5 weeks.Higher magnification of PAS‐stained sections. Scale bar: 250 μm.Data information: In (A, B), each dot represents one individual mouse. Bars indicate mean. ANOVA followed by the Tukey--Kramer test. \**P *\<* *0.05, *ns*: not statistically different.](EMBJ-37-e98615-g011){#embj201798615-fig-0005ev}

Our findings from *in vitro* systems and an ADPKD model demonstrate that PKD1 interacts with the LKB1 regulatory module to inhibit a ciliary signal inducing CCL2 (Fig [8](#embj201798615-fig-0008){ref-type="fig"}C). A *Pkd1* mutation releases the inhibitory signal, promoting increased levels of CCL2, the accumulation of CCR2^+^ mononuclear phagocytes, and cyst growth, while the ablation of cilia or inactivation of CCL2 in PKD1 mutant epithelial cells in the kidney prevents this cascade (Fig [8](#embj201798615-fig-0008){ref-type="fig"}D--F).

![Graphic summary\
Under normal conditions, NPHP1, ANKS3, NEK7, LKB1, and STRAD constitute a module within the cilium to inhibit a ciliary signal on CCL2.In the absence of LKB1 or STRAD, the block is released and a ciliary signal activates expression of CCL2. This leads to the recruitment of monocytes and macrophages expressing CCR2, the CCL2 receptor; remodeling; and fibrosis.PKD1 interacts with LKB1 and STRAD to activate the repressive function of the LKB1 module.Loss of PKD1 results in de‐repression of CCL2 expression by the module. This leads to the recruitment of monocytes and CCR2^+^ macrophages enhancing cyst growth.In the absence of cilia and PKD1, the ciliary CCL2 signal cannot be activated. The recruitment of mononuclear cells is inhibited, and less cyst growth occurs.Simultaneous targeting of PKD1 and CCL2 prevents the activation of mononuclear cells and ameliorates cyst growth.](EMBJ-37-e98615-g014){#embj201798615-fig-0008}

Discussion {#embj201798615-sec-0011}
==========

We define here that cilia of renal tubules actively regulate peritubular macrophage numbers. Cilia act as signal transducers to increase expression of the chemokine CCL2. The signal inducing CCL2 is regulated by a ciliary module involving LKB1, the ciliopathy proteins NPHP1, PKD1, and ANKS3, and NEK7. Genetic targeting of *Lkb1* or *Pkd1* in the kidney *in vivo* results in mononuclear phagocyte recruitment and the promotion of ciliopathy phenotypes. Ablation of cilia or CCL2 in *Pkd1* mutant mice prevents this pathophysiology and ameliorates the disease.

The loss of LKB1 in kidney tubules leads to a progressive disruption of renal architecture and function resembling a nephronophthisis phenotype. These events are characterized by inflammation and fibrosis and involve the secretion of CCL2 and expansion of CCR2^+^ macrophages. LKB1 regulates CCL2 by interacting with three proteins linked to NPHP, a ciliopathy occurring in children and adolescents. Among them is NPHP1, the protein most commonly mutated in genetically defined NPHP, and two interacting cilia proteins: ANKS3 and NEK7, the first of which is a ciliopathy protein itself. All of these proteins are required for CCL2 regulation.

The LKB1 regulatory module acts within cilia: LKB1 exerts its CCL2‐suppressive function only in the presence of the cilia‐specific LKB1 interactor STRADb, but not in its absence when only the cytosolic STRADa is present. In the absence of cilia, CCL2 does not increase, suggesting that cilia carry a positive signal regulating CCL2 which is blocked by the LKB1 module. This is supported *in vivo* by the finding that ablation of cilia or CCL2 together with PKD1 ameliorates the cystic phenotype in a similar manner.

Our findings suggest that this mechanism is relevant for the human ciliopathy ADPKD. Based on observations in orthologous mouse models that ablation of cilia ameliorates the ADPKD phenotype, it has been proposed that PKD1 blocks a cilia‐dependent cyst‐activating signal whose nature has not been specified (Ma *et al*, [2013](#embj201798615-bib-0050){ref-type="ref"}). Indeed, CCL2 is such a signal: We find that PKD1 interacts with LKB1 and its functional interactor STRAD. Loss of PKD1 *in vitro* and *in vivo* stimulates CCL2 expression in a cilia‐dependent way: In a PKD1 mouse model, we find that lack of cilia results in lower amounts of CCR2^+^ macrophages and decreased cyst formation. In addition, deletion of CCL2 concomitant with PKD1 in renal tubules reduces macrophage numbers and ameliorates cyst formation. These findings are consistent with previously published data showing that macrophage recruitment is a driving force for cyst growth in different animal models of PKD (Cowley *et al*, [2001](#embj201798615-bib-0017){ref-type="ref"}; Karihaloo *et al*, [2011](#embj201798615-bib-0042){ref-type="ref"}; Norman, [2011](#embj201798615-bib-0057){ref-type="ref"}; Chen *et al*, [2015](#embj201798615-bib-0015){ref-type="ref"}; Puri *et al*, [2016](#embj201798615-bib-0066){ref-type="ref"}). Indeed, in human patients CCL2 excretion in the urine has been found to be a marker of ADPKD progression (Zheng *et al*, [2003](#embj201798615-bib-0098){ref-type="ref"}), suggesting that the regulation of CCL2 by the ciliary LKB1 module is clinically important.

Could there also be a wider role for ciliary LKB1 in renal disease? Inflammation and fibrosis represent a final common pathway in different types of chronic renal disease (Cao *et al*, [2015](#embj201798615-bib-0012){ref-type="ref"}), but in a large number of cases, the inflammatory trigger is not established. In the German chronic kidney disease cohort, with over 5,000 participants, less than one‐third of the patients had an underlying chronic inflammatory disorder such as autoimmune disease (Titze *et al*, [2015](#embj201798615-bib-0083){ref-type="ref"}). Among the remaining patients, the causes were diabetes (15%), vascular (25%), or undetermined (21%). Both diabetes and vascular disease are metabolic disorders. Of note, LKB1 is a metabolic sensor and CCL2 signaling has been implicated in diabetic kidneys and vascular disease (Sayyed *et al*, [2011](#embj201798615-bib-0074){ref-type="ref"}; Bot *et al*, [2017](#embj201798615-bib-0006){ref-type="ref"}). This raises the possibility that in metabolic disease, the ciliary LKB1 module could confer an inflammatory phenotype on renal epithelial cells to mediate chronic inflammation in the kidney. Given that chronic kidney disease is now the tenth leading cause of death worldwide (Eckardt *et al*, [2013](#embj201798615-bib-0021){ref-type="ref"}; GBD2015‐Collaborators, [2016](#embj201798615-bib-0028){ref-type="ref"}), this is of considerable interest.

Liver kinase B1 might link cilia to inflammation also outside the kidney: Obesity and diabetes are states of energy excess, and metformin, an antidiabetic drug that augments the effect of LKB1 on AMPK, is particularly effective in obese diabetics (UKPDS Group, [1998](#embj201798615-bib-0087){ref-type="ref"}). Obesity and diabetes are accompanied by low‐grade inflammation in a positive feedback loop, particularly in adipose tissue, where adipocytes release CCL2 to recruit CCR2‐expressing monocytes (Weisberg *et al*, [2006](#embj201798615-bib-0091){ref-type="ref"}; Hotamisligil & Erbay, [2008](#embj201798615-bib-0037){ref-type="ref"}; Brestoff & Artis, [2015](#embj201798615-bib-0010){ref-type="ref"}). Diabetes‐associated inflammation also occurs in the heart, which similarly to the kidney develops interstitial fibrosis in diabetic subjects (Bugger & Abel, [2014](#embj201798615-bib-0011){ref-type="ref"}). Indeed, it has been shown that LKB1 deletion in the heart promotes fibrosis and heart failure (Ikeda *et al*, [2009](#embj201798615-bib-0038){ref-type="ref"}). A further setting where the link between LKB1 and inflammation may play a role is malignant disease: Somatic loss of LKB1 occurs in a variety of cancers, particularly cervical and lung cancer, which both carry a poor prognosis (Ji *et al*, [2007](#embj201798615-bib-0040){ref-type="ref"}; Wingo *et al*, [2009](#embj201798615-bib-0092){ref-type="ref"}). It is interesting in this respect that CCL2‐induced macrophage recruitment has been found to promote metastatic seeding of cancer cells (Qian *et al*, [2011](#embj201798615-bib-0067){ref-type="ref"}; Pena *et al*, [2015](#embj201798615-bib-0062){ref-type="ref"}) and that in pancreatic cancer, the presence of cilia correlates with more metastases and a worse prognosis (Emoto *et al*, [2014](#embj201798615-bib-0022){ref-type="ref"}).

In summary, we describe that cilia actively promote chemokine signaling and inflammation in the kidney and that this pathway is suppressed by a module involving LKB1, NPHP‐associated proteins, and PKD1. Loss of PKD1 activates the pathway and promotes disease progression in an orthologous model of ADPKD.

Materials and Methods {#embj201798615-sec-0012}
=====================

Mice {#embj201798615-sec-0013}
----

All animal experiments were conducted according to the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals, as well as the German law for the welfare of animals, and were approved by regional authorities (Regierungspräsidium Freiburg G‐13/18, G‐15/58, and G‐16/28). Mice were housed in a specific pathogen‐free facility, fed *ad libitum*, and housed at constant ambient temperature in a 12‐hour day/night cycle. Breeding and genotyping were done according to standard procedures.

*Lkb1* ^flox/flox^ mice (mixed genetic background) were purchased from The Jackson Laboratories (STOCK *Stk11* ^*tm1.1Sjm*^/J, stock number: 014143) and were crossed to *KspCre* mice (B6.Cg‐Tg(Cdh16‐cre)91lgr/J; C57Bl/6N background; Shao *et al*, [2002](#embj201798615-bib-0078){ref-type="ref"}) to generate a tubule‐specific Lkb1 knockout (further referred to as *Lkb1* ^ΔTub^). *Lkb1* ^flox/+^ and *Lkb1* ^flox/flox^ littermates without the *KspCre* transgene were used as controls. Experiments were conducted on both females and males.

For co‐immunoprecipitation studies, C57BL/6J male mice were used from the local stock of the animal facility of Freiburg University.

*Pkd1* ^flox/flox^ mice (B6.129S4‐Pkd1tm2Ggg/J, stock number: 010671, C57BL/6 genetic background) and Ccl2‐RFP^flox/flox^ (B6.Cg‐Ccl2tm1.1Pame/J, stock number: 016849, C57BL/6 genetic background) were purchased from The Jackson Laboratories, and *Kif3a* ^flox/flox^ mice (Kif3atm1Gsn, C57BL/6 genetic background) were kindly provided by Peter Igarashi and were crossed to *Pax8rtTA* (Traykova‐Brauch *et al*, [2008](#embj201798615-bib-0084){ref-type="ref"}) and *TetOCre* (Eremina *et al*, [2008](#embj201798615-bib-0024){ref-type="ref"}) mice to generate an inducible tubule‐specific *Pkd1* knockout (further referred to as i*Pkd1* ^ΔTub^), *Pkd1;Ccl2* knockout (further referred to as i*Pkd1* ^ΔTub^;i*Ccl2* ^ΔTub^), and *Pkd1;Kif3a* knockout (further referred to as i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^). From post‐natal day 28 (P28) to P42, mice received doxycycline hydrochloride (Fagron) via the drinking water (2 mg/ml with 5% sucrose, protected from light) for a period of 14 days. Littermates (lacking either TetOCre or Pax8rtTA) were used as controls. Experiments were conducted on males.

Zebrafish line maintenance and embryo manipulation {#embj201798615-sec-0014}
--------------------------------------------------

Zebrafish strains were maintained and raised as described (Epting *et al*, [2015](#embj201798615-bib-0023){ref-type="ref"}). Transgenic *wt1b::GFP* zebrafish embryos (Perner *et al*, [2007](#embj201798615-bib-0063){ref-type="ref"}) were injected with 0.5 mM morpholino (MO; Gene Tools LLC) targeting *lkb1* (5′‐GAGATCCGCGCCCACGCTCATCTTT‐3′ as described; Jacob *et al*, [2011](#embj201798615-bib-0039){ref-type="ref"}) or *nphp1* (5′‐CCCTCTTCTCTTTGGAGGCATGTTG‐3′ as described; Slanchev *et al*, [2011](#embj201798615-bib-0081){ref-type="ref"}) at the one‐cell stage. All MOs were co‐injected with 0.1 mM p53 MO (5′‐GCGCCATTGCTTTGCAAGAATTG‐3′) to reduce the unspecific effects of the reagents. To correct for the amount of total MO in the combined knockdown experiment, 0.5 mM standard control MO (5′‐CCTCTTACCTCAGTTACAATTTATA‐3′) was simultaneously injected. Embryos were analyzed at 48--50 h.p.f. under a Leica MZ16 stereo microscope (Leica). Images were recorded using a Leica DFC450 C (Leica).

Magnetic resonance imaging {#embj201798615-sec-0015}
--------------------------

Magnetic resonance imaging was performed on anesthetized animals at 10 and 16 weeks of age using a 9.4‐T (400 MHz) horizontal magnet equipped with a 38‐mm‐inner‐diameter quadrature birdcage coil (Bruker Biospin), as previously described (Grahammer *et al*, [2014](#embj201798615-bib-0029){ref-type="ref"}). Briefly, anesthesia was induced with isoflurane, and breathing and heart rate were monitored by ECG. Fast imaging technique and cardiac gating were applied to reduce motion artifacts. A fast spin‐echo sequence (TR/TEeff/FA: 4,800 ms/36 ms/180°; echo train length, 8) was used to achieve T2 contrast. The sequence featured a 30 × 30 mm field of view, a matrix size of 256 × 256 pixels, and an in‐plane resolution of 117 × 117 mm. The slice thickness was 0.5 mm with no slice spacing to achieve contiguous image sets of the whole volume. Morphological analyses were performed using Medical Image Processing and Visualization (MIPAV) software (National Institutes of Health). To determine the total kidney volume, the perimeter of the kidney, which could be clearly distinguished from the surrounded tissue, was delineated manually on each slice image. The total kidney volume was calculated from sets of contiguous images by summing up the products of area measurements and slice thickness using the volume of interest tool in MIPAV as previously described (Grahammer *et al*, [2014](#embj201798615-bib-0029){ref-type="ref"}).

Urine and plasma analyses {#embj201798615-sec-0016}
-------------------------

Eight‐hour urine samples were obtained from mice housed in individual boxes without access to water and food. Body weight and urine excretion were measured. Urine osmolality was measured with a freezing point depression osmometer (Micro‐Osmometer from Knauer or OSMOMAT 3000 basic from Gonotec). Retro‐orbital blood was collected from anesthetized mice. Plasma blood urea nitrogen (BUN) was measured using urea kit (LT‐UR; Labor&Technik, Eberhard Lehmann GmbH) according to the manufacturer\'s instructions.

Transmission electron microscopy {#embj201798615-sec-0017}
--------------------------------

Transmission electron microscopy was performed as previously described (Grahammer *et al*, [2014](#embj201798615-bib-0029){ref-type="ref"}). Briefly, 4% paraformaldehyde perfusion‐fixed kidneys were post‐fixed in 1% glutaraldehyde/4% paraformaldehyde for 24 h at 4°C. Subsequently, kidneys were post‐fixed in 1% osmium tetroxide (Roth) for 1 h and then with 1% uranyl acetate in 70% EtOH overnight at 4°C (Polysciences), dehydrated, and embedded in Durcupan resin (Plano). Ultrathin sections were performed using a UC6 ultramicrotome (Leica), collected on Formvar (Plano)‐coated copper grids, and imaged using a Philips CM 100 transmission electron microscope.

Scanning electron microscopy {#embj201798615-sec-0018}
----------------------------

For scanning electron microscopy, 4% paraformaldehyde perfusion‐fixed kidneys were post‐fixed in 1% glutaraldehyde/4% paraformaldehyde for 24 h at 4°C and were subsequently dehydrated in ethanol (70--100%---each step for 1 h at RT). Dehydrated kidney samples were then incubated with the solvent HMDS in a 1:1 solution with EtOH for 30 min. The final dehydration was then performed in 100% HMDS. Kidney samples were dissected using syringe needles under a binocular microscope. Sputtering with gold was performed using a Polaron Cool Sputter Coater E 5100. Samples were visualized using a scanning electron microscope (Leo 1450 VP scanning).

Morphological analysis {#embj201798615-sec-0019}
----------------------

Mouse kidneys were fixed in 4% paraformaldehyde and embedded in paraffin, and 4‐μm sections were stained with periodic acid--Schiff (PAS) or Picrosirius Red. PAS‐stained sections were imaged using an AxioPlan2 (Zeiss) equipped with a Plan Neofluar 20×/0.30 NA objective and an AxioCam camera (Zeiss). PAS‐stained full‐size images were recorded using an AxioObserver Z1 (Zeiss) equipped with an EC Plan Neofluar 2.5×/0.085 NA objective and an AxioCam camera (Zeiss) or using a whole slide scanner, Nanozoomer 2.0 (Hamamatsu), equipped with a 20×/0.75 NA objective coupled to NDPview software (Hamamatsu). Picrosirius Red‐stained sections were imaged using an AxioImager Z1 (Zeiss) equipped with a Plan Apochromat 40×/0.95 NA objective and an AxioCam camera (Zeiss). Image recording was performed using AxioVision software (Zeiss) or ZenBlue Software (Zeiss).

Plasmids {#embj201798615-sec-0020}
--------

Tagged constructs for CD2AP, GFP, NPHP1, NPHP2, NPHP3, NPHP4, and NPHP8 were previously described (Hoff *et al*, [2013](#embj201798615-bib-0035){ref-type="ref"}). Tagged LKB1 and STRADa constructs were kindly provided by Andrea Thiele from Hubrecht Lab and Clevers Lab, respectively. STRADb was cloned from Clone 3549243 (BioScience). FLAG.MO25a and FLAG.MO25b were cloned from canine cDNA into pcDNA6 in‐frame with N‐terminal FLAG tag. FLAG.PKD1 construct was kindly provided by Michael Caplan (Grimm *et al*, [2003](#embj201798615-bib-0030){ref-type="ref"}). Flag.LKB1 for rescue experiment was cloned from human cDNA into pLXSN in‐frame with Flag tag. YFP.LKB1, STRADa.YFP, and STRADb.YFP were cloned from human cDNA into pLXSN in‐frame with N‐terminal (LKB1) or C‐terminal (STRAD constructs) YFP variant. The primers used for cloning are listed in [Appendix Table S1](#embj201798615-sup-0001){ref-type="supplementary-material"}.

Cell culture, transfections, co‐immunoprecipitation, and transgenic cell lines {#embj201798615-sec-0021}
------------------------------------------------------------------------------

Human embryonic kidney (HEK 293T) cells (ATCC Promocell; CRL‐11268) are listed in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample and were authenticated by Interspecies Determination (Isoenzyme Analysis and STR Analysis) by the providing company. HEK 293T cells were cultured using Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum (Biochrom). Plasmids were transiently transfected using calcium. For co‐immunoprecipitation, cells were lysed in CHAPS buffer (40 mM HEPES pH 7.5, 120 mM NaCl, 1 mM EDTA, 0.30% CHAPS) supplemented with 1 mM Na~3~VO~4~, 50 mM NaF, 5 mM β‐glycerophosphate, and protease inhibitor cocktail tablet (Roche) using a 20‐G needle. Equal amounts of protein were incubated with anti‐V5‐agarose (Abcam, ab1229) or anti‐FLAG M2 affinity gel (Sigma‐Aldrich, A2220) and processed by Western blotting.

Madin‐Darby canine kidney (MDCK, kind gift from Prof. Kai Simons, MPI‐CBG, Dresden, Germany) cells were cultured using Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum and 1% penicillin--streptomycin (Sigma). To generate MDCK cell lines for tetracycline‐inducible knockdown of target genes, a lentivirus‐based transduction system (pLVTH) was used as previously described (Wiznerowicz & Trono, [2003](#embj201798615-bib-0093){ref-type="ref"}). The shRNA targeting sequences used were as follows: *Anks3*‐i1 (5′‐GGAAGATGACCTCTGCCATTG‐3′), *Anks3*‐i2 (5′‐GGAGGATCGAGTCCAGGAAAT‐3′), *Ift88*‐i (5′‐GAAGGCAGCTGAATTCTAT‐3′), *Kif3a*‐i (5′‐AGGCTAGAGCTGAATTAGAG‐3′), *Lkb1*‐i1 (5′‐GCTGGTGGACGTGTTATAC‐3′), *Lkb1*‐i2 (5′‐GGTGGACGTGTTATACAAT‐3′), *Luciferase* (5′‐CGTACGCGGAATACTTCGA‐3′), *Nek7*‐i1 (5′‐GAGTCATGCATAGAGATATAA‐3′), *Nek7*‐i2 (5′‐CCAGCTAATGTGTTCATTACA‐3′), *Nphp1*‐i (5′‐GGTTCTCAGTAGACATGTA‐3′; Delous *et al*, [2009](#embj201798615-bib-0019){ref-type="ref"}), *Nphp4*‐i (5′‐GCCCATCGGTGTCTACACA‐3′; Delous *et al*, [2009](#embj201798615-bib-0019){ref-type="ref"}), *Strada*‐i (5′‐CAAGTACAGTGTCAAGGTTCT‐3′), and *Stradb*‐i (5′‐GAACACAAGTTGAATCACTCA‐3′). The efficiency of the knockdown was verified by Quantitative real‐time PCR (qRT--PCR) as described below (primer list in [Appendix Table S1](#embj201798615-sup-0001){ref-type="supplementary-material"}) and/or Western blot. YFP.NPHP1‐, Flag.LKB1 (rescue)‐, YFP.LKB1‐, STRADa.YFP‐, and STRADb.YFP‐expressing MDCK lines were generated with a retroviral transduction system (pLXSN) as previously described (Boehlke *et al*, [2010a](#embj201798615-bib-0004){ref-type="ref"}). *Pkd1*‐null MDCK cell lines were engineered with transcription activator‐like effector nucleases (TALENs) as described (Hofherr *et al*, [2017](#embj201798615-bib-0036){ref-type="ref"}). Loss of *Pkd1* was validated by genomic PCR and RT--PCR (primer list in [Appendix Table S1](#embj201798615-sup-0001){ref-type="supplementary-material"}). For CCL2 expression analysis, 150,000 cells/cm² were seeded with or without tetracycline (5 μg/ml) for 6 days on polycarbonate membranes (COSTAR, 3401). Total RNAs were extracted after 5 hours of serum deprivation with or without AICAR treatment (1 mM; LC Laboratories), and qRT--PCR was performed (primer list in [Appendix Table S1](#embj201798615-sup-0001){ref-type="supplementary-material"}). For immunofluorescence experiments, 150,000 cells/cm² cells were seeded for 10 days on glass coverslip coated with polylysine with or without tetracycline stimulation. All cells were regularly tested for mycoplasma contamination and were mycoplasma‐free.

Quantitative real‐time PCR {#embj201798615-sec-0022}
--------------------------

Total RNAs were obtained from whole kidneys or cells using RNeasy Mini Kit (Qiagen) and reverse‐transcribed using SuperScript III First‐Strand Synthesis SuperMix for qRT--PCR (Invitrogen) according to the manufacturer\'s protocol. qRT--PCR was performed on a LightCycler 480 (LC 480, Roche). *Gapdh*,*Sdha, Hprt*, and/or *Rpl13* were used as the normalization controls (Vandesompele *et al*, [2002](#embj201798615-bib-0088){ref-type="ref"}). Each biological replicate was measured in technical duplicates. The primers used for qRT--PCR are listed in [Appendix Table S1](#embj201798615-sup-0001){ref-type="supplementary-material"}.

Western blot {#embj201798615-sec-0023}
------------

Fresh kidney medulla was homogenized in lysis buffer (50 mM Tris pH 8, 200 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1% SDS) or CHAPS lysis buffer using a Dounce homogenizer. MDCK cells were lysed in RIPA buffer (20 mM Tris pH 8, 160 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1% SDS, 1% NP‐40, 1% Na deoxycholate, 1% Triton X‐100) using a 20‐G needle. Lysis buffers were supplemented with 1 mM Na~3~VO~4~, 50 mM NaF, 5 mM β‐glycerophosphate, and protease inhibitor cocktail tablet (Roche). Protein content was determined with Pierce BCA protein assay kit (Thermo Fisher Scientific). Equal amounts of protein were resolved on 4--15% Mini‐PROTEAN TGX™ Gel (Bio‐Rad) under reducing conditions, transferred, incubated with primary and secondary antibodies, and visualized on film according to standard protocols. Band density was calculated and normalized using LabImage 1D L340 software.

CCL2 ELISA {#embj201798615-sec-0024}
----------

For CCL2 measurement, 150,000 MDCK cells/cm² were seeded with or without tetracycline (5 μg/ml) for 8 days on polycarbonate membranes (COSTAR, 3401). Cell culture supernatants were collected after 24 hours of serum deprivation, and particulates were removed by centrifugation. Canine CCL2 was measured using ELISA (Canine CCL2/MCP‐1 Quantikine ELISA kit, R&D Systems, CACP00). Specimens, standards, and reagents were prepared according to the manufacturer\'s instructions.

Immunohistochemistry {#embj201798615-sec-0025}
--------------------

Four‐micrometer sections of paraffin‐embedded kidneys were submitted to antigen retrieval and avidin/biotin blocking (Vector, SP‐2001). Sections were incubated with primary antibody followed by biotinylated antibody, HRP‐labeled streptavidin (Southern Biotech, 7100‐05, 1:500), and 3,3′‐diaminobenzidine‐tetrahydrochloride (DAB) revelation. Images were recorded as described above.

Immunofluorescence {#embj201798615-sec-0026}
------------------

Four‐micrometer sections of paraffin‐embedded kidneys, or cells seeded on glass coverslip coated with polylysine (Sigma) were submitted to antigen retrieval and avidin/biotin blocking or cell permeabilization. The sections or coverslips were incubated with primary antibody and subsequently with the Alexa Fluor‐conjugated secondary antibodies or rhodamine‐labeled Dolichos Biflorus Agglutinin (DBA, Vector Laboratories, RL‐1032, 1:100). Images were recorded using an Axiovert 200 M (Zeiss) and AxioVision software (Zeiss). Confocal imaging was performed on an LSM 510 Duo microscope (ZEISS) using ZenBlack Software (Zeiss).

Flow cytometry and cell sorting {#embj201798615-sec-0027}
-------------------------------

After perfusion with 10 ml cold, sterile PBS, kidneys from 10‐week‐old *Lkb1* ^ΔTub^ mice and littermate controls or 12‐week‐old i*Pkd1* ^ΔTub^ mice, i*Pkd1* ^ΔTub^;i*Kif3a* ^ΔTub^ mice, and littermate controls were harvested, de‐capsulated, minced with fine scissors, placed into a mixture of collagenase D (Worthington Biochemical) and DNase I (Roche), and shaken at 37°C for 35 min, as previously described (Triantafyllopoulou *et al*, [2010](#embj201798615-bib-0085){ref-type="ref"}). The cell suspension was centrifuged at 500 *g* for 6 min at 4°C. Cells were then triturated through nylon mesh to obtain single‐cell suspensions and stained with primary antibody, DAPI (Molecular Probes) followed by Streptavidin V500 (BD Horizon) to label biotinylated antibodies. Flow cytometry was performed using a BD LSR Fortessa cytometer (BD Biosciences), and the results were analyzed with FlowJo software (TreeStar).

Mass spectrometry {#embj201798615-sec-0028}
-----------------

Kidneys from 15‐week‐old C57BL/6J male mice (*n *=* *6) were perfused with ice‐cold PBS supplemented with 1 mM Na~3~VO~4~, 50 mM NaF, 5 mM β‐glycerophosphate, and protease inhibitor cocktail tablet (Roche) and the medulla separated from the cortex and homogenized in CHAPS lysis buffer as described above. After lysate pre‐clearing with protein G‐conjugated Sepharose beads (GE Healthcare), 10 mg was incubated on a rotating wheel for 2 h at 4°C with 50 μg antibody. Protein G‐conjugated Sepharose beads were added and incubated on a rotating wheel for 1 h at 4°C. The beads were collected by centrifugation and washed five times with CHAPS lysis buffer. Protein was eluted by heating in 2× Laemmli buffer containing 100 mM DTT followed by alkylation using 120 mM iodoacetamide for 20 min at 20°C in the dark. Protein mixtures were separated by SDS--PAGE (4--12% Bis‐Tris mini gradient gel) and the lanes cut into five equal slices and in‐gel digested with trypsin. The resulting peptide mixtures were processed on STAGE tips (Rappsilber *et al*, [2007](#embj201798615-bib-0069){ref-type="ref"}). Three independent biological replicates were analyzed. Samples were measured on LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific) coupled either to an Agilent 1200 nanoflow HPLC (Agilent Technologies GmbH) or to an Eksigent NanoLC Ultra. HPLC‐column tips (fused silica) with 75 μm inner diameter were self‐packed with Reprosil‐Pur 120 ODS‐3 to a length of 20 cm. No pre‐column was used. Peptides were injected at a flow of 500 nl/min in 92% buffer A (0.5% acetic acid in HPLC gradient‐grade water) and 2% buffer B (0.5% acetic acid in 80% acetonitrile, 20% water). Separation was achieved by a linear gradient from 10% to 30% of buffer B at a flow rate of 250 nl/min. The mass spectrometer was operated in the data‐dependent mode and switched automatically between Mass spectrometry (MS) (max. of 1 × 10 ions) and MS/MS. Each MS scan was followed by a maximum of five MS/MS scans in the linear ion trap using normalized collision energy of 35% and a target value of 5,000. Parent ions with a charge state of *z* = 1 and unassigned charge states were excluded from fragmentation. The mass range for MS was m/z = 370 to 2,000. The resolution was set to 60,000. MS parameters were as follows: spray voltage 2.3 kV; no sheath and auxiliary gas flow; and ion transfer tube temperature 125°C.

MS data analysis {#embj201798615-sec-0029}
----------------

The MS raw data files were uploaded into the MaxQuant software version 1.4.1.2 (Cox & Mann, [2008](#embj201798615-bib-0018){ref-type="ref"}), which performs peak detection and generates peak lists of mass error‐corrected peptides and database searches. A full‐length mouse database containing common contaminants, such as keratins and enzymes used for in‐gel digestion (based on IPI human version 3.68), was employed, carbamidomethylcysteine was set as fixed modification, and methionine oxidation and protein amino‐terminal acetylation were set as variable modifications. Three miss cleavages were allowed, enzyme specificity was trypsin/P, and the MS/MS tolerance was set to 0.5 Da. The average mass precision of identified peptides was in general \< 1 ppm after recalibration. Peptide lists were further used by MaxQuant to identify and relatively quantify proteins using the following parameters: peptide; and protein false discovery rates (FDR) were set to 0.01; maximum peptide posterior error probability (PEP) was set to 0.1; minimum peptide length was set to 6; minimum number peptides for identification and quantification of proteins was set to 1, which at least was unique; and identified proteins have been re‐quantified.

Antibodies {#embj201798615-sec-0030}
----------

Antibodies were used against the following:

*For Western blotting*: AMPKα (Cell Signaling Technology, 2532, 1:1,000), ANKS3 (Eurogentec, rabbit polyclonal, directed against mouse ANKS3 556--656, 1:1,000), α‐TUBULIN (Sigma, T5168, 1:20,000), β‐ACTIN (Sigma, A1978, 1:60,000), FLAG (M2 clone, Sigma, F‐3165, 1:6,000), IFT88 (ProteinTech, 13967‐1‐AP, 1:1,000), KIF3a (BD Transduction, 611508, 1:1,000), LKB1 (D60C5F10, Cell Signaling Technology, 13031, 1:6,000), NEK7 (Santa Cruz Biotechnology, sc‐50756 and sc‐393539, 1:1,000), NPHP1 (rabbit polyclonal, kind gift from Prof. Bernhard Schermer, Köln, 1:4,000), pAMPKα^T172^ (Cell Signaling Technology, 2535, 1:1,000), PKD1 (7E12, Santa Cruz Biotechnology, sc‐130554, 1:200), pS6RP^S235/236^ (Cell Signaling Technology, 4858, 1:2,000), pTSC2^S1387^ (Cell Signaling Technology, 5584, 1:1,000), S6RP (Cell Signaling Technology, 2217, 1:1,000), TSC2 (Cell Signaling Technology, 4302, 1:1,000), and V5 (AbD Serotec, MCA1360, 1:5,000).

*For immunostaining on kidney sections or MDCK cells*: acetyl‐alpha‐tubulin (Lys40) (D20G3, Cell Signaling Technology, 5335, 1:100), acetylated tubulin (Sigma, T6793, 1:250), ANKS3 (for kidney sections: Eurogentec, rabbit polyclonal, directed against mouse ANKS3 290‐395, 4 μg/mL; and for MDCK cells: Novus Biologicals, NB100‐61625, 1:100), AQP1 (Santa Cruz Biotechnology, sc‐20810, 1:500), AQP2 (Santa Cruz Biotechnology, sc‐9882, 1:500), F4/80 (Clone Cl:A3‐1, Bio‐Rad, MCA497R, 1:100), GFP (Abcam, ab13970, 1:400), IgG (Santa Cruz Biotechnology, sc‐2027, 4 μg/ml), LKB1 (D60C5F10, Cell Signaling Technology, 13031, 1:1,000 for kidney section, 1:100 for MDCK cells), pAMPKα^T172^ (Cell Signaling Technology, 2535, 1:100), pS6RP^S235/236^ (Cell Signaling Technology, 4858, 1:100), and THP (Serotec, 8595‐0054, 1:500).

*For flow cytometry*: The following antibodies were used: CD45 (30‐F11), B220 (RA3‐6B2), CD3 (145‐2C11), CD19 (MB19‐1), CD5 (53‐7.3), CD11b (M1/70) (all from eBioscience), NK1.1 (PK136; BD Pharmingen), Ly6G (1A8; BD Bioscience), F4/80 (Bio‐Rad), and CCR2 (48607; R&D Systems).

*For immunoprecipitation assay*: goat anti‐LKB1 (M‐18, Santa Cruz Biotechnology, sc‐5640) and goat IgG (Santa Cruz Biotechnology, sc‐2028).

Mouse microarray gene expression {#embj201798615-sec-0031}
--------------------------------

Total RNAs were extracted and purified from 5‐week‐old control and *Lkb1* ^ΔTub^ kidneys (five mice per genotype), using RNeasy Mini Kit (Qiagen) according to the manufacturer\'s protocol. RNA quality was checked using a Fragment Analyzer™ (Advanced Analytical Technologies). cDNAs were generated and hybridized on Affymetrix GeneChip^®^ Mouse Transcriptome Arrays 1.0 according to the GeneChip^®^ WT Plus assay protocol. Arrays were normalized using the Robust Multichip Algorithm (RMA) and mapped to transcript clusters using the R Bioconductor packages oligo (version 1.36.1; Carvalho & Irizarry, [2010](#embj201798615-bib-0013){ref-type="ref"}) and mta10sttranscriptcluster.db (version 8.4). Downstream analysis considered only Entrez‐annotated transcripts. If multiple transcripts mapped to the same Entrez ID, the one with the largest interquartile range between samples was chosen.

RNAseq gene expression in MDCK cells {#embj201798615-sec-0032}
------------------------------------

Total RNA was obtained and verified as described above from MDCK cells with and without tetracycline‐induced knockdown of LKB1 (two independent experiments per condition). Sequencing of fragmented cDNA was carried out on a HiSeq 2500 instrument (Illumina) at GATC Biotech Laboratory (Konstanz, Germany). The 50‐bp paired‐end reads were pseudo‐aligned to the dog transcriptome (CanFam3.1) and quantified using kallisto (Bray *et al*, [2016](#embj201798615-bib-0009){ref-type="ref"}). Downstream analysis considered only Entrez‐annotated transcripts.

Microarray and RNAseq data analysis {#embj201798615-sec-0033}
-----------------------------------

Principal component analysis was done using the R labdsv package (version 1.8). Counts from the RNAseq data were log2‐transformed prior to analysis, and only the 1,000 most varying transcripts were considered. Differential gene expression was calculated using limma (Ritchie *et al*, [2015](#embj201798615-bib-0070){ref-type="ref"}) and sleuth (Pimentel *et al*, [2017](#embj201798615-bib-0064){ref-type="ref"}) for the mouse microarray and dog RNAseq data, respectively, using *q* \< 0.05 as significance cutoff. Functional enrichment of differentially regulated genes was calculated from a conditional hypergeometric test as implemented in the R Bioconductor GOstats package (Falcon & Gentleman, [2007](#embj201798615-bib-0025){ref-type="ref"}) (*P* \< 0.05), and semantic similarity among GO terms was measured via the GOSemSim package (Yu *et al*, [2010](#embj201798615-bib-0096){ref-type="ref"}).

Statistical analysis {#embj201798615-sec-0034}
--------------------

Data were expressed as means or as means ± SD. Differences between the experimental groups were evaluated using one‐way ANOVA, followed when significant (*P *\<* *0.05) by the Tukey--Kramer test. When only two groups were compared, two‐tailed paired *t*‐test or the Mann--Whitney test was used as appropriate. For Kaplan--Meier survival curves, log‐rank test was applied. The statistical analysis was performed using GraphPad Prism V6 software. For cell culture, the normal distribution of experiment replicates was systematically assumed. For animal studies, the aspect of the distribution was used to assume or not the normal distribution. Differences in variance were determined when multiple groups were compared by ANOVA. The sample size of mice was predetermined by a biostatistician. No samples were excluded from analysis. All image analyses (immunohistochemistry, immunofluorescence, MRI, FACS immunophenotyping) and mouse phenotypic analysis were performed in a blinded fashion.

Data availability {#embj201798615-sec-0035}
-----------------

Microarray data and RNAseq data have been deposited at GEO and are available under the ID GSE86011.
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Correction added on 1 August 2018 after first online publication: This sentence and new reference Han *et al* ([2016](#embj201798615-bib-0400){ref-type="ref"}) were added.
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